NSE: MEDPLUS· HealthCareCore · Aug 26Small cap

Medplus Health Services

Organised pharmacy retail

Last close
₹654.00
29 Sept 2026 · reference
1D · 1M
+0.2% · −3.3%
price-only
Weight
0.8%
31 Jul 2026 · Aug rank 27
Thesis review
8 Sep 2026
Why We Own, p43
Coverage owner: Research (per book); latest results Q Jun-26Screener ↗Tijori ↗NSE ↗
Map

What must happen → what could break it → what we watch

Catalysts · 3
  • Q2FY27 results (Oct/Nov-2026): private-label share rebuilding by 0.3-0.4pp QoQ and operating EBITDA margin recovering from 3.5%.
    C1
  • Delivery on 800 net store adds in FY27 with franchise mix rising (capital-light growth).
    C2
  • Any resolution/reduction of the promoter pledge (60.7%) would remove the main governance overhang.
    C3
Material risks · 3
  • Promoter pledge: 60.7% of promoter holding (40.2%) is pledged, with promoter-level debt of ~Rs 1,150 cr incl. interest disclosed on the Q1FY27 call.
    R1
  • Margin squeeze from wage inflation (salaries +30% YoY) and weak private-label uptake; 27 young franchise stores already closed (avg 0.7 yrs old).
    R2
  • Competition from Apollo 24/7, Tata 1mg and quick-commerce medicine delivery (Blinkit/Zepto) in metros, where online is forecast to reach 20% share by 2031.
    R3
Live monitors
  • Valuation vs approved target
    No target stated
  • Latest reported quarter
    Q Jun-26
  • Results-driven thresholds
    Awaiting approved numbers

Catalysts and risks are the approved one-pager text in full; the register below adds owners and review dates. Monitors read from the price and fundamentals feeds.

Risks as a decision framework

Material risks

Risk register
#Risk (approved text)Owner · next review
01Promoter pledge: 60.7% of promoter holding (40.2%) is pledged, with promoter-level debt of ~Rs 1,150 cr incl. interest disclosed on the Q1FY27 call.Research · post 2QFY27
02Margin squeeze from wage inflation (salaries +30% YoY) and weak private-label uptake; 27 young franchise stores already closed (avg 0.7 yrs old).Research · post 2QFY27
03Competition from Apollo 24/7, Tata 1mg and quick-commerce medicine delivery (Blinkit/Zepto) in metros, where online is forecast to reach 20% share by 2031.Research · post 2QFY27

Exposure mechanism, impact and mitigants are as written in the book. Leading indicators and numeric triggers not stated in the approved text remain research tasks rather than being invented.

Catalysts

Observable events

  • 01Q2FY27 results (Oct/Nov-2026): private-label share rebuilding by 0.3-0.4pp QoQ and operating EBITDA margin recovering from 3.5%.
  • 02Delivery on 800 net store adds in FY27 with franchise mix rising (capital-light growth).
  • 03Any resolution/reduction of the promoter pledge (60.7%) would remove the main governance overhang.
Monitors

Live monitors from available data

  • ClearValuation exceeding the approved range: reference close 654 vs base target not stated.
  • DataLatest reported quarter in fundamentals: Q Jun-26. Results-driven monitors (growth below thesis threshold, margin, credit cost) need approved numeric thresholds; none in the book.
  • DataInput-cost and capital-allocation monitors require licensed commodity/filings feeds — not configured.